Prana Biotechnology Limited

Penelope Jane Huggins

Jack Gordon Parsons

Kevin Jeffrey Barnham

Elisabeth Colette Louise Gautier

Antony Vincent Robinson

Ashley Bush

Ashley I Bush

Gaik Beng Kok

Vijaya Kenche

Gaik Being Kok

Colin Louis Masters

Mariana El Sous

Michael Mcnaughton

The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders. 

4H-pyrido[1,2-a]pyrimidin-4-one compounds

4H-pyrido[1,2-A]pyrimidin-4-one compounds

The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions.

Method of treatment of age-related macular degeneration (AMD)

The present invention relates to quinazolinone compounds, processes for their preparation and their use as pharmaceutical agents for the treatment of Parkinson's disease (PD). The quinazolinone compounds are of general formula (I). 

Quinazolinone compounds

The present invention relates generally to therapeutic agents, formulations comprising them and their use in the treatment, amelioration and/or prophylaxis of glioma brain tumors and related conditions. The therapeutic agent comprises two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxyl at position 8.

Use of pyridopyrimidine compounds in the treatment of gliomas

Growing community of inventors

Murrumbeena, Australia

Penelope Jane Huggins